Novo Nordisk Strikes €1.17 Billion Nanexa Drug Delivery Deal 
U.S. Issues Cuba Health Alert as Illnesses Rise 
Circle Stock Falls 4% as Crypto Selloff Overshadows SAP Pay Expansion 
Trump Administration Releases New UFO Files and Apollo Mission Records 
SpaceX Seeks $40 Billion for Nvidia AI Chips 
Asian Stocks Rise as Nasdaq Record Offsets Bond Yield Pressure 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
Securitize, LG CNS Partner on South Korea Tokenization 
New York Declares Measles Disaster Emergency as Cases Surge 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Nasdaq Hits Record High as Tech Stocks Lift Wall Street 
Bitmine to Stop Ethereum Buying After Reaching 5% ETH Supply 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
World Bank Raises South Asia Growth Forecast to 6.9% 
S&P 500 Hits Record High as AI Rally Lifts Wall Street 
Jared Isaacman Confirmed as NASA Administrator, Becomes 15th Leader of U.S. Space Agency 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Add as a preferred source on Google
Korea Ginseng Corp. said that a collaborative research team that it co-supports with Konyang University has found a potential mechanism in red ginseng polysaccharides that reduces cognitive decline in Alzheimer's disease.
The mechanism that red ginseng polysaccharides are related to synaptic and mitochondrial pathways in Alzheimer's disease was identified in this year’s research.
With an analysis of the protein-protein interaction of 111 proteins significantly changed by injecting red ginseng polysaccharide in mice, the research team found that the protein interaction decreased significantly.
Bioinformatics analysis confirmed that these proteins play an important role in nerve and synaptic development and function related to Alzheimer's disease, contributing to the preservation of mitochondrial forms.
How red ginseng polysaccharides do this was not fully clarified due to a lack of research two years ago.
"This study is meaningful because it has confirmed the possibility of red ginseng polysaccharides as candidates for effective treatments of Alzheimer's disease in animal models,” said Moon Min-ho, a professor at the College of Medicine at Konyang University.
In 2021, Konyang University’s Research Institute for Dementia Science, led by Professor Moon Min-ho, and Korea Ginseng Corporation's Research Institute team, led by Lee Yong-yook, announced in the international scientific journal Free Radical Biology and Medicine that red ginseng polysaccharide inhibits amyloid beta aggregation.
Alzheimer's occurs when amyloid beta, a proposed cause of Alzheimer's, aggregates and accumulates in the brain.
